Key result
Early in-hospital initiation of SGLT2 inhibitors increased the likelihood of in-hospital ARNI introduction compared to delayed initiation.
Why the study?
The management of acute heart failure is crucial and challenging, with uncertainty about the impact of early levosimendan use on hemodynamic stabilization and rapid optimization of guideline-directed medical therapy.
Does early in-hospital initiation of SGLT2 inhibitors facilitate the in-hospital introduction of ARNI in patients with HFrEF?
Cohort (n=285)
No
Does early in-hospital initiation of SGLT2 inhibitors facilitate the in-hospital introduction of ARNI in patients with HFrEF?
Early in-hospital initiation of SGLT2 inhibitors facilitates more rapid and comprehensive implementation of guideline-directed medical therapy, specifically ARNI, in patients with HFrEF.
Answers are grounded in this paper and cite their sources.
Early SGLT2 inhibitor initiation was associated with higher ARNI use in HFrEF; hypothesis-generating and requires randomized confirmation before practice change.
PURPOSE: The management of acute heart failure (AHF) is crucial and challenging. Regarding the use of inotropes, correct patient selection and time of administration are of the essence. We hypothesize that the early use of Levosimendan favouring hemodynamic stabilization and enables rapid optimization of guideline-directed medical therapy (GDMT) in patients with HF, eventually impacting the patient's prognosis during the vulnerable phase. METHODS: This prospective, observational study enrolled consecutive patients admitted due to AHF. Propensity score matching (PSM) analysis has been used to homogenize differences between groups. In group 1 (G1), patients were treated with early 24-h Levosimendan infusion followed by in-hospital introduction/up-titration of GDMT. In group 2 (G2), patients were treated with alternative inotropes/ vasopressors followed by in-hospital introduction/up-titration of GDMT. The comparison between the two groups has been performed at the 6-month follow-up in terms of cardiovascular (CV) mortality and HF hospitalizations (HFH). RESULTS: 233 patients were included in the present study, and after propensity match adjustments, 176 patients were analysed, 88 patients for each group. No differences in the baseline characteristics have been reported between the groups. At 6 months follow-up, no statistically significant differences were shown in terms of the composite endpoint of CV death and HFH (p = 0.445) and CV death (p = 0.62). Statistically significant differences between the two groups were reported in terms of HFH (p = 0.02). The Kaplan-Meier survival analysis showed that patients in G1 were significantly less hospitalized compared to G2 during the 6 months after the index hospitalization (log-rank p = 0.03). CONCLUSION: Early 24-hour infusion of Levosimendan followed by rapid optimization of HF diseasemodifying therapies results in a significant reduction of HFH in the vulnerable post-discharge phase.
No takes yet. Share an insight, caveat, or question.
Severino et al. (2025) conducted a cohort in HFrEF (n=285). Early in-hospital initiation of SGLT2 inhibitors vs. Delayed SGLT2 inhibitor initiation (after hospital discharge) was evaluated on In-hospital introduction of ARNI (OR 3.307, 95% CI 1.872-5.840, p=<0.001). Early in-hospital initiation of SGLT2 inhibitors increased the likelihood of in-hospital ARNI introduction compared to delayed initiation.
Synapse has enriched 10 related papers. Consider them for comparative context: